JP2016505546A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505546A5
JP2016505546A5 JP2015545453A JP2015545453A JP2016505546A5 JP 2016505546 A5 JP2016505546 A5 JP 2016505546A5 JP 2015545453 A JP2015545453 A JP 2015545453A JP 2015545453 A JP2015545453 A JP 2015545453A JP 2016505546 A5 JP2016505546 A5 JP 2016505546A5
Authority
JP
Japan
Prior art keywords
kabat
cdr
vegf
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015545453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505546A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072335 external-priority patent/WO2014085654A1/en
Publication of JP2016505546A publication Critical patent/JP2016505546A/ja
Publication of JP2016505546A5 publication Critical patent/JP2016505546A5/ja
Ceased legal-status Critical Current

Links

JP2015545453A 2012-11-30 2013-11-27 抗vegf抗体及びこれらの使用 Ceased JP2016505546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732256P 2012-11-30 2012-11-30
US61/732,256 2012-11-30
PCT/US2013/072335 WO2014085654A1 (en) 2012-11-30 2013-11-27 Anti-vegf antibodies and their uses

Publications (2)

Publication Number Publication Date
JP2016505546A JP2016505546A (ja) 2016-02-25
JP2016505546A5 true JP2016505546A5 (enExample) 2017-01-12

Family

ID=49765713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545453A Ceased JP2016505546A (ja) 2012-11-30 2013-11-27 抗vegf抗体及びこれらの使用

Country Status (11)

Country Link
US (2) US20140154255A1 (enExample)
EP (1) EP2925778B1 (enExample)
JP (1) JP2016505546A (enExample)
CN (1) CN104903348A (enExample)
AU (1) AU2013352127A1 (enExample)
BR (1) BR112015012538A2 (enExample)
CA (1) CA2892164A1 (enExample)
ES (1) ES2649966T3 (enExample)
HK (1) HK1215446A1 (enExample)
MX (1) MX2015006859A (enExample)
WO (1) WO2014085654A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Vegf/dll4結合劑類及彼等之用途
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド 抗vegf抗体の最適化変異体
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017119434A1 (ja) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Vegfとnrp1との結合を阻害する抗体
IL262207B2 (en) * 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
US11254738B2 (en) 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
CN110283248B (zh) * 2018-01-05 2020-07-28 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111363038A (zh) * 2020-03-26 2020-07-03 北京纽安博生物技术有限公司 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
WO2022197866A1 (en) * 2021-03-16 2022-09-22 City Of Hope Anti-hvem antibodies
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1579871A1 (en) 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6979559B2 (en) 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
BR0116680A (pt) 2000-12-14 2005-04-05 Genentech Inc Linhagem de e. coli e método de produção de um polipeptìdeo
EP1356052B1 (en) 2000-12-14 2008-08-20 Genentech, Inc. Production of full antibodies in procaryotic cells
CA2369893A1 (en) 2001-02-12 2002-08-12 Warner-Lambert Company Vegf responsive cell-based assay for determining vegf bioactivity
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
US20040010376A1 (en) 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA04007583A (es) 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
CA2485732A1 (en) 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック, インコーポレイテッド プロテインaアフィニティークロマトグラフィーの間のプロテインaの浸出の低減
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
MX2007004374A (es) 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
WO2006043972A1 (en) 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20080207467A1 (en) 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
WO2007059336A1 (en) 2005-11-18 2007-05-24 Nextrom Oy Method and apparatus for manufacturing water-free optical fiber preforms
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
CN101415415A (zh) 2006-01-23 2009-04-22 约瑟夫·P·埃里科 定向药物开发的方法和组合物
ES2603399T3 (es) 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
RU2567639C2 (ru) * 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
US20120077691A1 (en) 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2014078866A2 (en) * 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses

Similar Documents

Publication Publication Date Title
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2018183173A5 (enExample)
JP2018505177A5 (enExample)
JP2023134618A5 (enExample)
JP2016512551A5 (enExample)
JP2017534577A5 (enExample)
JP2012530496A5 (enExample)
JP2011046732A5 (enExample)
JP2021514973A5 (enExample)
JP2019501883A5 (enExample)
JP2016536020A5 (enExample)
JP2024056687A5 (enExample)
JP2019536806A5 (enExample)
JP2020520370A5 (enExample)
JP2015509947A5 (enExample)
JP2018510617A5 (enExample)
JP2018506277A5 (enExample)
JP2018035138A5 (enExample)
JP2011506483A5 (enExample)
JP2014158469A5 (enExample)
JP2017535257A5 (enExample)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2018507220A5 (enExample)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2015509948A5 (enExample)